Merus (NASDAQ:MRUS) Major Shareholder Purchases $6,427,608.00 in Stock

by · The Cerbat Gem

Merus N.V. (NASDAQ:MRUS – Get Free Report) major shareholder A/S Genmab purchased 66,264 shares of the stock in a transaction on Friday, December 19th. The shares were purchased at an average price of $97.00 per share, with a total value of $6,427,608.00. Following the acquisition, the insider owned 72,013,065 shares in the company, valued at approximately $6,985,267,305. The trade was a 0.09% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

A/S Genmab also recently made the following trade(s):

  • On Thursday, December 18th, A/S Genmab bought 212,177 shares of Merus stock. The stock was purchased at an average price of $97.00 per share, for a total transaction of $20,581,169.00.
  • On Wednesday, December 17th, A/S Genmab acquired 150,795 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, for a total transaction of $14,627,115.00.
  • On Tuesday, December 16th, A/S Genmab purchased 120,752 shares of Merus stock. The stock was acquired at an average cost of $97.00 per share, for a total transaction of $11,712,944.00.

Merus Stock Up 0.0%

Merus stock opened at $96.93 on Thursday. The firm’s fifty day moving average is $95.79 and its 200 day moving average is $76.77. Merus N.V. has a 12-month low of $33.19 and a 12-month high of $97.14. The company has a market capitalization of $7.35 billion, a PE ratio of -18.29 and a beta of 1.06.

Analysts Set New Price Targets

Several equities analysts recently weighed in on MRUS shares. Needham & Company LLC cut shares of Merus from a “buy” rating to a “hold” rating and set a $96.00 price target on the stock. in a research report on Monday, September 29th. Leerink Partnrs downgraded Merus from a “strong-buy” rating to a “hold” rating in a research note on Sunday, October 5th. Barclays reiterated an “equal weight” rating and set a $97.00 target price (down previously from $112.00) on shares of Merus in a research report on Tuesday, September 30th. Canaccord Genuity Group cut Merus from a “buy” rating to a “hold” rating and lifted their price target for the company from $67.00 to $97.00 in a research report on Monday, September 29th. Finally, HC Wainwright cut shares of Merus from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $135.00 to $97.00 in a research note on Monday, September 29th. Three equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $93.56.

Get Our Latest Analysis on MRUS

Hedge Funds Weigh In On Merus

A number of large investors have recently added to or reduced their stakes in the business. FNY Investment Advisers LLC increased its stake in Merus by 199.1% in the 3rd quarter. FNY Investment Advisers LLC now owns 6,000 shares of the biotechnology company’s stock worth $564,000 after purchasing an additional 3,994 shares during the period. Hudson Bay Capital Management LP raised its holdings in Merus by 2,188.6% in the third quarter. Hudson Bay Capital Management LP now owns 740,394 shares of the biotechnology company’s stock worth $69,708,000 after purchasing an additional 775,843 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in Merus during the 3rd quarter valued at about $68,838,000. Swiss Life Asset Management Ltd purchased a new position in shares of Merus during the third quarter valued at approximately $238,000. Finally, Polar Asset Management Partners Inc. raised its stake in Merus by 870.1% during the third quarter. Polar Asset Management Partners Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $4,708,000 after buying an additional 44,846 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

(Get Free Report)

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.

Featured Articles